Allergan, Inc.

Allergan Botox Patent Infringement Trial Against Revance Set for July in Delaware

- A Delaware federal judge has ruled that Allergan's patent infringement lawsuit against Revance Therapeutics will proceed to trial in July 2024, following the denial of summary judgment motions from both parties. - The case centers on allegations that Revance's botulinum toxin product Daxxify infringes six Allergan patents related to Botox formulations and stabilization methods. - The court dismissed two Allergan entities from the litigation, leaving Allergan Inc. as the sole plaintiff after ruling that Allergan Ireland lacked standing due to insufficient proof of exclusive licensing rights. - Revance's Daxxify product received FDA approval for frown lines treatment in 2022 and cervical dystonia in 2023, despite delays caused by COVID-19 pandemic and inspection deficiencies.